Appropriateness and limitations of modified Response Evaluation Criteria in Solid Tumors (mRECIST) in evaluating the efficacy of molecular-targeted therapy for patients with hepatocellular carcinoma
-
- Takeda Haruhiko
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
-
- Osaki Yukio
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
-
- Inuzuka Tadashi
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
-
- Nakajima Jun
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
-
- Matsuda Fumihiro
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
-
- Sakamoto Azusa
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
-
- Hatamaru Keiichi
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
-
- Henmi Shinichiro
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
-
- Ishikawa Tetsuro
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
-
- Saito Sumio
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
-
- Nishikawa Hiroki
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
-
- Kita Ryuichi
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
-
- Kimura Toru
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
Bibliographic Information
- Other Title
-
- 肝細胞癌の分子標的薬治療効果判定におけるmodified RECISTの妥当性と問題点～当院での経験より
- キモ サイボウガン ノ ブンシ ヒョウテキヤク チリョウ コウカ ハンテイ ニ オケル modified RECIST ノ ダトウセイ ト モンダイテン : トウ イン デ ノ ケイケン ヨリ
Search this article
Abstract
Modified Response Evaluation Criteria in Solid Tumors (mRECIST), which was proposed by Lencioni et al, is novel criteria used to evaluate the efficacy of molecular-targeted therapy (MTT) in patients with hepatocellular carcinoma by measuring the largest diameter of the enhanced area in the arterial phase of dynamic computed tomography. We have encountered several limitations of mRECIST. Here, we discussed these limitations and presented some impressive cases. One of the main limitations is whether we can regard the disappearance of arterial blood flow as a complete response. Moreover, several other limitations were noted as well. It is thought that mRECIST may be more useful than conventional RECIST in many cases. However, it should be recognized that mRECIST is not appropriate in all cases. We need to evaluate the clinical effects with medical images and tumor markers in clinical practice.<br>
Journal
-
- Kanzo
-
Kanzo 53 (3), 147-154, 2012
The Japan Society of Hepatology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001204794987904
-
- NII Article ID
- 10030547259
-
- NII Book ID
- AN00047770
-
- ISSN
- 18813593
- 04514203
-
- NDL BIB ID
- 023522976
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed